Regado Biosciences (Regado Biosciences) Effective Interest Rate on Debt % : 8.19% (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Regado Biosciences Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Regado Biosciences's annualized positive value of Interest Expense for the quarter that ended in Jun. 2016 was $1.24 Mil. Regado Biosciences's average total debt for the quarter that ended in Jun. 2016 was $15.15 Mil. Therefore, Regado Biosciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2016 was 8.19%.

Regado Biosciences Effective Interest Rate on Debt % Historical Data

The historical data trend for Regado Biosciences's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regado Biosciences Effective Interest Rate on Debt % Chart

Regado Biosciences Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Effective Interest Rate on Debt %

5.02

17.22

15.19

16.15

34.76

Regado Biosciences Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Effective Interest Rate on Debt %	Get a 7-Day Free Trial														31.75	8.92	8.51	8.15	8.19

Competitive Comparison of Regado Biosciences's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Regado Biosciences's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regado Biosciences's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regado Biosciences's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Regado Biosciences's Effective Interest Rate on Debt % falls into.

Regado Biosciences Effective Interest Rate on Debt % Calculation

Regado Biosciences's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2015 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2014 )	+	Total Debt (A: Dec. 2015 ))	/ count )
=	-1 * -3.091	/	( (2.669	+	15.114)	/ 2 )
=	-1 * -3.091	/	8.8915
=	34.76 %

where

	Total Debt (A: Dec. 2014 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.04	+	2.629
=	2.669

	Total Debt (A: Dec. 2015 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	15.091	+	0.023
=	15.114

Regado Biosciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2016 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Mar. 2016 )	+	Total Debt (Q: Jun. 2016 ))	/ count )
=	-1 * -1.24	/	( (15.114	+	15.176)	/ 2 )
=	-1 * -1.24	/	15.145
=	8.19 %

where

	Total Debt (Q: Mar. 2016 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	13.981	+	1.133
=	15.114

	Total Debt (Q: Jun. 2016 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	12.629	+	2.547
=	15.176

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jun. 2016) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Regado Biosciences (NAS:RGDO) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Regado Biosciences Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regado Biosciences (Regado Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tobiratherapeutics.com

Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.

Executives

Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p.	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron	director	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper	director	BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz	officer: Chief Financial Officer	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines